Penetration into solid tumor tissue of fluorescent latex microspheres: A mimic of liposome particles

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 3005-3008

  Pan, Xing Q ^a,c   Lee, Robert J ^a   Ratnam, Manohar ^b  

^a College of Pharmacy ^*  (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Fluorescent latex microspheres; Liposome; Solid tumor

Indexed keywords

CD31 ANTIGEN; FLUORESCENT DYE; FLUORESCENT LATEX MICROSPHERE; LATEX; LIPOSOME; MICROSPHERE; RHODAMINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CELL NUCLEUS; CONTRAST MEDIUM EXTRAVASATION; EXPERIMENTAL NEOPLASM; FLUORESCENCE; FLUORESCENCE MICROSCOPY; L1210JF TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL;

ANIMALS; BLOOD VESSELS; FLUORESCENT DYES; LATEX; LEUKEMIA L1210; LIPOSOMES; MALE; MICE; MICE, INBRED DBA; MICROSPHERES; RHODAMINES;

EID: 6444236972     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ostro MJ: Liposomes. Scientific American 256: 103-111, 1987.
2. Bangham AD: Liposome: Realizing their promise. Hosp Pract 27: 51-62, 1993.
3. Patel J: Liposomal doxorubicin: doxil. J Oncol Practice 2: 201-210, 1996.
4. Sapra P and Allen TM: Ligand-targeted liposomal anticancer drugs. Progress in Lipid Research 42: 439-462, 2003.
5. Lu Y and Low PS: Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Del Rev 54: 675-693, 2002.
6. Nagayasu A, Uchiyama K and Kiwada H: The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Del Rev 40: 75-87, 1999.
7. Foren D, Horowitz AT, Tzemach D, Tarshih M, Zalipsky S and Gabizon A: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6: 1949-1957, 2000.
8. Hovorka O, Stastny M, Etrych T, Subr V, Strohalm J, Ulbrich K and Rihova B: Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release 80: 101-117, 2002.
9. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S and Allen TM: Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochimica et Biophysica Acta 1515: 144-158, 2001.
10. Jain RK: Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 74: 7-25, 2001.
11. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK and McDonald DM: Openings between defective endothelial cells explain tumor vessel leakiness. Am Soc Invest Pathol 156: 1363-1380, 2000.
12. Kohn S, Nagy JA, Dvorak HF and Dvorak AM: Pathways of macromolecular tracer transport across venules and small veins: structural basis for the hyperpermeability of tumor blood vessels. Lab Invest 67: 596-607, 1992.
13. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Sioussat TM and Dvorak HF: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55: 360-368, 1995.
14. Lichtenbeld HC, Yuan F, Michel CC and Jain RK: Perfusion of single tumor microvessels: application to vascular permeability measurement. Microcirculation 3: 349-357, 1996.
15. Dvorak HF, Nagy JA, Feng D, Brown LF and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237: 97-132, 1999.
16. Sharma US, Sharma A, Chau RI and Straubinger RM: Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharmaceutical Res 14: 992-998, 1997.
17. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F and Jain RK: Augmentation of transcular transport of macromoleculesand nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59: 4129-4135, 1999.
18. Rubin MA, Buyyounouski M, Bagilla E, Sharir S, Neugut A, Benson M, Taille A, Katz AE, Olsson CA and Ennis RD: Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53: 542-547, 1999.
19. Rogatsch H, Hittmair A, Reissigl A, Mikuz G and Feichtinger H: Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor. J Pathol 1821: 205-210, 1997.
20. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM: Indentification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-109, 1988.
21. Hobbs SK, Monsky WL, Yuan F, Roberts G, Griffith L, Torchilin VP and Jain RK: Regulation of transport pathways in tumor vessels: role of tumor type and microenviroment. Proc Natl Acad Sci USA 95: 4607-4612, 1998.
22. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ and Jain RK: Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 15: 778-783, 1997.
23. Baban DF and Seymour LW: Control of tumor vascular permeability. Adv Drug Del Rev 34: 109-119, 1998.
24. Katz LC, Burkhalter A and Dreyer WJ: Fluorescent latex microspheres as a retrograde neuronal marker for in vivo and in vitro studies of visual cortex. Nature 310: 498-500, 1984.
25. Riddle DR, Lo DC and Katz LC: NT-4-mediated rescue of lateral geniculate neurons from effects of monocular deprivation. Nature 378: 189-191, 1995.
26. Crosland RD and Canziani GA: Detection of sparse botulinum toxin A binding site using fluorescent latex microspheres. J Histotechnology 22: 113-115, 1999.
27. Fujimura Y and Owen RL: Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit peyer's patches. Transplantation 73: 1049-1954, 2002.
28. Pan XQ, Wang H and Lee RJ: Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharmaceutical Res 20: 417-422, 2003.
29. Pan XQ, Zheng X, Shi GF, Wang H, Ratnam M and Lee RJ: Strategy for the treatment of acute myelogenous leukemia based on folate receptor β-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100: 594-602, 2002.
30. Lee RJ and Low PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1233: 134-144, 1995.